Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

Valentina Guarnotta, Manuela Albertelli, Annamaria Colao, Erika Maria Grossrubatscher, Giovanni Vitale, Giovanna Muscogiuri, Pasqualino Malandrino, Genoveffa Pizza, Manila Rubino, Andrea Isidori, Federica Grillo, Carla Di Dato, Roberta Modica, Federica De Cicco, Fabio Lo Calzo, Elia Guadagno, Barbara Altieri, Laura Rizza, Sergio Di Molfetta, Concetta SciammarellaFrancesco Ferraù, Annamaria Colao, Erika Messina, Chiara Martini, Elisa Giannetta, Elena Ambrosetti, Antonio Bianchi, Giovanni Vitale, Silvia Carra, Lena Bottiglieri, Giovanni Vitale, Paola Razzore, Maria Chiara Zatelli, Giuseppe Fanciulli, Antonella Di Sarno, Antongiulio Faggiano, Rosaria Maddalena Ruggeri, Diego Ferone, Severo Campione, Elisa Giannetta, Marco Gallo

    Risultato della ricerca: Articlepeer review

    5 Citazioni (Scopus)

    Abstract

    PURPOSE:Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC.METHODS:The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic.RESULTS:We performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies evaluating these issues: Are there any predictive criteria of response to immunotherapy? What is the correct place of immunotherapy in the treatment algorithm of MCC? What is the best choice after immunotherapy failure? What to do with patients for whom immunotherapy is not been feasible or contraindicated? How long should immunotherapy be prolonged, and what follow-up should be offered after complete response?CONCLUSION:The therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited
    Lingua originaleEnglish
    pagine (da-a)429-443
    Numero di pagine15
    RivistaJournal of Cancer Research and Clinical Oncology
    Volume145
    Stato di pubblicazionePublished - 2019

    All Science Journal Classification (ASJC) codes

    • ???subjectarea.asjc.2700.2730???
    • ???subjectarea.asjc.1300.1306???

    Fingerprint

    Entra nei temi di ricerca di 'Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions'. Insieme formano una fingerprint unica.

    Cita questo